# Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW

> **NCT06355609** · PHASE2 · RECRUITING · sponsor: **Hunan Province Tumor Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** sunvozertinib in combination with Anlotinib

## Key facts

- **NCT ID:** NCT06355609
- **Lead sponsor:** Hunan Province Tumor Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2025-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06355609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06355609, "Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06355609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*